ArticleJournal of virology2020
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells.
Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 209 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
209 citing papers in PubMed, 9 syntheses or guidelines pooled it, 295 citations in OpenAlex.
- The influence of prior use of inhaled corticosteroids on COVID-19 outcomes: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Individual risk factors associated with SARS-CoV-2 infection during Alpha variant in high-income countries: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- The association between inhaled corticosteroid and the risks of SARS-COV-2 infection: A systematic review and meta-analysis.Journal of infection and public health · 2023Pooled it
- Clinical efficacy of inhaled corticosteroids in patients with coronavirus disease 2019: A living review and meta-analysis.PloS one · 2023Pooled it
- Risk of serious COVID-19 outcomes among adults and children with moderate-to-severe asthma: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2022Pooled it
- Effect of comorbid pulmonary disease on the severity of COVID-19: A systematic review and meta-analysis.Respirology (Carlton, Vic.) · 2021Pooled it
- Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.Advances in therapy · 2020Pooled it
- Underlying respiratory diseases, specifically COPD, and smoking are associated with severe COVID-19 outcomes: A systematic review and meta-analysis.Respiratory medicine · 2020Pooled it
- Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective.The European respiratory journal · 2020Pooled it
- Intranasal Corticosteroid Treatment on Recovery of Long-Term Olfactory Dysfunction Due to COVID-19.The Laryngoscope · 2022Trial
- Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE).Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Trial
- Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial.JAMA internal medicine · 2022Trial
- Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial.BMJ (Clinical research ed.) · 2021Trial
- Molecular insights into the anti-COVID-19 activity of reduced (quinol) and oxidized (quinone) forms of coenzyme Q10.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Allergen-specific immunotherapy in rhinitis patients is associated with milder COVID-19 symptoms and improved quality of life.Clinics (Sao Paulo, Brazil) · 2026Article
- Post-COVID-19 Physical Activity and Symptom Burden in Patients with Asthma and COPD Compared with Individuals Without Chronic Disease: A Multicenter Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa.BMC medicine · 2026Article
- Exploring potential phytocompounds from black cumin as drug molecules against SARS-CoV-2 infections through bioinformatics analysis.PloS one · 2026Article
- Association of Inhaled Corticosteroid Use with COVID-19 Severity and Hospitalization in Patients With and Without Respiratory Disease.Journal of aerosol medicine and pulmonary drug delivery · 2025Article
- Impact of the COVID-19 Pandemic on Lung Function and Treatment Decisions in Children with Asthma: A Retrospective Study.Journal of clinical medicine · 2025Article
149 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we screened steroid compounds to obtain a drug expected to block host inflammatory responses and Middle East respiratory syndrome coronavirus (MERS-CoV) replication. Ciclesonide, an inhaled corticosteroid, suppressed the replication of MERS-CoV and other coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), in cultured cells. The 90% effective concentration (EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.